Recent advances in stroke management

Gregory W. Albers, Mark J. Alberts, Joseph P. Broderick, Patrick D. Lyden, Ralph L. Sacco

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Major advances in stroke treatment and prevention have occurred over the last several years. Recent studies have documented that appropriate modification of stroke risk factors can lead to a substantial reduction in stroke incidence. In addition, a variety of new risk factors, such as elevated plasma homocysteine levels, antiphospholipid antibodies, and specific genetic factors, are being recognized. The most significant advance in acute stroke therapy is the use of intravenous tissue plasminogen activator (t-PA) for treatment of patients with ischemic stroke within 3 hours of symptom onset. T-PA is currently the only stroke treatment approved by the Federal Drug Administration. There continues to be uncertainty and misunderstanding regarding the risks and benefits of this therapy. A variety of neuroprotective agents have been highly successful for reducing ischemic brain injury in animal stroke models. Recent clinical trials with these agents, however, have not produced beneficial effects in humans. Newer neuroprotective agents with more favorable safety profiles and improvements in clinical trial design may lead to therapeutic successes in the near future. It is apparent that both thrombolytic and neuroprotective treatments for acute stroke must be administered very rapidly after stroke onset. Therefore, acute stroke teams are being developed to facilitate rapid diagnostic evaluation and treatment of stroke patients.

Original languageEnglish (US)
Pages (from-to)95-105
Number of pages11
JournalJournal of Stroke and Cerebrovascular Diseases
Volume9
Issue number3
StatePublished - 2000

Fingerprint

Stroke
Neuroprotective Agents
Therapeutics
Clinical Trials
Antiphospholipid Antibodies
Homocysteine
Tissue Plasminogen Activator
Brain Injuries
Uncertainty
Animal Models
Safety
Incidence
Pharmaceutical Preparations

Keywords

  • Neuroprotective therapy
  • Stroke centers
  • Stroke risk factors
  • Thrombolysis

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery
  • Health Professions(all)

Cite this

Albers, G. W., Alberts, M. J., Broderick, J. P., Lyden, P. D., & Sacco, R. L. (2000). Recent advances in stroke management. Journal of Stroke and Cerebrovascular Diseases, 9(3), 95-105.

Recent advances in stroke management. / Albers, Gregory W.; Alberts, Mark J.; Broderick, Joseph P.; Lyden, Patrick D.; Sacco, Ralph L.

In: Journal of Stroke and Cerebrovascular Diseases, Vol. 9, No. 3, 2000, p. 95-105.

Research output: Contribution to journalArticle

Albers, GW, Alberts, MJ, Broderick, JP, Lyden, PD & Sacco, RL 2000, 'Recent advances in stroke management', Journal of Stroke and Cerebrovascular Diseases, vol. 9, no. 3, pp. 95-105.
Albers GW, Alberts MJ, Broderick JP, Lyden PD, Sacco RL. Recent advances in stroke management. Journal of Stroke and Cerebrovascular Diseases. 2000;9(3):95-105.
Albers, Gregory W. ; Alberts, Mark J. ; Broderick, Joseph P. ; Lyden, Patrick D. ; Sacco, Ralph L. / Recent advances in stroke management. In: Journal of Stroke and Cerebrovascular Diseases. 2000 ; Vol. 9, No. 3. pp. 95-105.
@article{6efb9370077e4d51bd6157429210e345,
title = "Recent advances in stroke management",
abstract = "Major advances in stroke treatment and prevention have occurred over the last several years. Recent studies have documented that appropriate modification of stroke risk factors can lead to a substantial reduction in stroke incidence. In addition, a variety of new risk factors, such as elevated plasma homocysteine levels, antiphospholipid antibodies, and specific genetic factors, are being recognized. The most significant advance in acute stroke therapy is the use of intravenous tissue plasminogen activator (t-PA) for treatment of patients with ischemic stroke within 3 hours of symptom onset. T-PA is currently the only stroke treatment approved by the Federal Drug Administration. There continues to be uncertainty and misunderstanding regarding the risks and benefits of this therapy. A variety of neuroprotective agents have been highly successful for reducing ischemic brain injury in animal stroke models. Recent clinical trials with these agents, however, have not produced beneficial effects in humans. Newer neuroprotective agents with more favorable safety profiles and improvements in clinical trial design may lead to therapeutic successes in the near future. It is apparent that both thrombolytic and neuroprotective treatments for acute stroke must be administered very rapidly after stroke onset. Therefore, acute stroke teams are being developed to facilitate rapid diagnostic evaluation and treatment of stroke patients.",
keywords = "Neuroprotective therapy, Stroke centers, Stroke risk factors, Thrombolysis",
author = "Albers, {Gregory W.} and Alberts, {Mark J.} and Broderick, {Joseph P.} and Lyden, {Patrick D.} and Sacco, {Ralph L.}",
year = "2000",
language = "English (US)",
volume = "9",
pages = "95--105",
journal = "Journal of Stroke and Cerebrovascular Diseases",
issn = "1052-3057",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Recent advances in stroke management

AU - Albers, Gregory W.

AU - Alberts, Mark J.

AU - Broderick, Joseph P.

AU - Lyden, Patrick D.

AU - Sacco, Ralph L.

PY - 2000

Y1 - 2000

N2 - Major advances in stroke treatment and prevention have occurred over the last several years. Recent studies have documented that appropriate modification of stroke risk factors can lead to a substantial reduction in stroke incidence. In addition, a variety of new risk factors, such as elevated plasma homocysteine levels, antiphospholipid antibodies, and specific genetic factors, are being recognized. The most significant advance in acute stroke therapy is the use of intravenous tissue plasminogen activator (t-PA) for treatment of patients with ischemic stroke within 3 hours of symptom onset. T-PA is currently the only stroke treatment approved by the Federal Drug Administration. There continues to be uncertainty and misunderstanding regarding the risks and benefits of this therapy. A variety of neuroprotective agents have been highly successful for reducing ischemic brain injury in animal stroke models. Recent clinical trials with these agents, however, have not produced beneficial effects in humans. Newer neuroprotective agents with more favorable safety profiles and improvements in clinical trial design may lead to therapeutic successes in the near future. It is apparent that both thrombolytic and neuroprotective treatments for acute stroke must be administered very rapidly after stroke onset. Therefore, acute stroke teams are being developed to facilitate rapid diagnostic evaluation and treatment of stroke patients.

AB - Major advances in stroke treatment and prevention have occurred over the last several years. Recent studies have documented that appropriate modification of stroke risk factors can lead to a substantial reduction in stroke incidence. In addition, a variety of new risk factors, such as elevated plasma homocysteine levels, antiphospholipid antibodies, and specific genetic factors, are being recognized. The most significant advance in acute stroke therapy is the use of intravenous tissue plasminogen activator (t-PA) for treatment of patients with ischemic stroke within 3 hours of symptom onset. T-PA is currently the only stroke treatment approved by the Federal Drug Administration. There continues to be uncertainty and misunderstanding regarding the risks and benefits of this therapy. A variety of neuroprotective agents have been highly successful for reducing ischemic brain injury in animal stroke models. Recent clinical trials with these agents, however, have not produced beneficial effects in humans. Newer neuroprotective agents with more favorable safety profiles and improvements in clinical trial design may lead to therapeutic successes in the near future. It is apparent that both thrombolytic and neuroprotective treatments for acute stroke must be administered very rapidly after stroke onset. Therefore, acute stroke teams are being developed to facilitate rapid diagnostic evaluation and treatment of stroke patients.

KW - Neuroprotective therapy

KW - Stroke centers

KW - Stroke risk factors

KW - Thrombolysis

UR - http://www.scopus.com/inward/record.url?scp=0033911519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033911519&partnerID=8YFLogxK

M3 - Article

C2 - 17895205

AN - SCOPUS:0033911519

VL - 9

SP - 95

EP - 105

JO - Journal of Stroke and Cerebrovascular Diseases

JF - Journal of Stroke and Cerebrovascular Diseases

SN - 1052-3057

IS - 3

ER -